U.S. Biopharmaceuticals Contract Manufacturing Market To Reach $19.54 Billion By 2030

U.S. Biopharmaceuticals Contract Manufacturing Market Growth & Trends

The U.S. biopharmaceuticals contract manufacturing market is anticipated to reach USD 19.54 billion by 2030 and expand at a CAGR of 10.6% from 2025 to 2030, according to a new report by Grand View Research, Inc.The U.S. biopharmaceuticals contract manufacturing market is growing due to the rising demand for biologics and biosimilars, which address complex diseases with innovative therapies. Advancements in manufacturing technologies, such as single-use systems and continuous processing, enhance production efficiency and scalability. These factors enable contract manufacturers to meet the rising need for cost-effective and high-quality biopharmaceuticals, driving market growth and fostering innovation in the industry.

The market thrives due to a focus on cost-effective production and the expansion of Contract Manufacturing Organizations (CMOs). By outsourcing manufacturing, companies reduce operational costs and allocate resources for innovation. CMOs provide scalable solutions, advanced technologies, and specialized expertise, ensuring efficient production. Their growth enables biopharma companies to meet the rising demand for biologics and biosimilars, driving market expansion and fostering innovation in industry.

The growing prevalence of chronic diseases fuels the demand for advanced biopharmaceuticals, including biologics and biosimilars, to address complex health challenges. Simultaneously, technological innovations in bioprocessing, such as single-use systems and continuous manufacturing, are revolutionizing production efficiency and scalability. These advancements empower contract manufacturers to meet the rising need for high-quality, cost-effective therapies and contribute significantly to the growth and evolution of the biopharmaceutical industry in the U.S.

 Request a free sample copy or view report summary: U.S. Biopharmaceuticals Contract Manufacturing Market Report

U.S. Biopharmaceuticals Contract Manufacturing Market Report Highlights

• By source, the mammalian segment held the largest share in 2024, owing toits critical role in producing biologics like monoclonal antibodies and recombinant proteins.

• By service, the process development segment led the market with the largest revenue share of 34.8% in 2024, driven byits pivotal role in optimizing production efficiency and ensuring regulatory compliance.

• Theanalytical & QC studies segment is set to grow at the fastest CAGR over the forecast period, fueled bythe increasing need for stringent quality assurance and regulatory compliance in biopharmaceutical production.

• By products, the biologics segment dominated the market with the largest share in 2024 due toincreasing demand for advanced therapies like monoclonal antibodies, cell and gene therapies, and biosimilars.

• The biosimilars segment is projected to be the fastest-growing segment from 2025 to 2030, attributed to increasing demand for cost-effective alternatives to biologics.

U.S. Biopharmaceuticals Contract Manufacturing Market Segmentation

Grand View Research has segmented the U.S. biopharmaceuticals contract manufacturing market based on source, service, products, type, scale of operation, and therapeutic area:

U.S. Biopharmaceuticals Contract Manufacturing SourceOutlook (Revenue, USD Billion, 2018 - 2030)

• Mammalian

• Non-mammalian

U.S. Biopharmaceuticals Contract Manufacturing ServiceOutlook (Revenue, USD Billion, 2018 - 2030)

• Process Development

  • Downstream

  • Upstream

• Fill & Finish Operations

• Analytical & QC Studies

• Packaging & Labelling

• Others

U.S. Biopharmaceuticals Contract Manufacturing ProductsOutlook (Revenue, USD Billion, 2018 - 2030)

• Biologics

  • Monoclonal Antibodies (mAbs)

  • Recombinant Proteins

  • Vaccines

  • Antisense, RNAi, & Molecular Therapy

  • Others

• Biosimilars

U.S. Biopharmaceuticals Contract Manufacturing TypeOutlook (Revenue, USD Billion, 2018 - 2030)

• Drug Substance

• Finished Drug Product

U.S. Biopharmaceuticals Contract Manufacturing Scale Of OperationOutlook (Revenue, USD Billion, 2018 - 2030)

• Clinical

• Commercial

U.S. Biopharmaceuticals Contract Manufacturing Therapeutic AreaOutlook (Revenue, USD Billion, 2018 - 2030)

• Oncology

• Autoimmune Diseases

• Infectious Diseases

• Cardiovascular Diseases

• Metabolic Diseases

• Neurology

• Others

List of Key Players in the U.S. Biopharmaceuticals Contract Manufacturing Market

• Lonza

• WuXi Biologics

• FUJIFILM Diosynth Biotechnologies

• Boehringer Ingelheim International GmbH

• Thermo Fisher Scientific Inc.

• Samsung Biologics

• AGC Biologics

• Catalent, Inc

• Rentschler Biopharma SE

• Eurofins Scientific